The ANXA11 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, generated from the human HeLa cell line with targeted disruption of the ANXA11 gene. This product serves as a robust loss-of-function model for investigating ANXA11-dependent cellular processes in an epithelial cancer context. The polyclonal format ensures a diverse genetic background, reflecting the heterogeneous nature of gene editing outcomes while maintaining functional knockout of the target gene. These cells are designed for advanced research applications requiring stable ablation of ANXA11 expression, without necessitating clonal isolation.
The host HeLa cell line is an immortalized epithelial line, originally derived from a cervical adenocarcinoma, and is positive for human papillomavirus type 18 (HPV-18). HeLa cells are among the most extensively utilized models in cancer biology, offering robust growth characteristics, ease of transfection, and well-characterized signaling pathways. Their epithelial origin makes them particularly suitable for studying processes such as cell adhesion, migration, and membrane dynamics, all of which are relevant to ANXA11 function. The HPV-18 status also introduces a viral oncoprotein context, which can be valuable for exploring interactions between viral pathogenesis and host cell machinery.
ANXA11 is a member of the annexin family, functioning as a calcium-dependent phospholipid-binding protein that orchestrates membrane trafficking, apoptosis, and cell adhesion. Mechanistically, ANXA11 is activated by elevated intracellular calcium and cellular stress, and acts downstream of growth factors such as PDGF and EGF. It interacts directly with ALG2 (PDCD6) and S100A6, forming complexes that regulate vesicle fusion and membrane repair. In apoptotic signaling, ANXA11 interacts with phosphatidylserine and Annexin A2, and modulates the activity of Caspase-3, a key executor of apoptosis, with links to the Bcl-2 family. Thus, ANXA11 serves as a critical node integrating calcium signals, membrane dynamics, and cell death pathways.
In the HeLa cellular context, knockout of ANXA11 is expected to disrupt calcium-dependent membrane repair and vesicle-mediated transport, leading to altered apoptotic responses and potential changes in cell adhesion and migration. Given HeLa cells’ widespread use in cancer research, this knockout model provides a platform to dissect how ANXA11 loss affects malignant phenotypes such as proliferation, survival, and invasive potential. The model is particularly relevant to diseases like sarcoidosis and amyotrophic lateral sclerosis, where ANXA11 mutations have been implicated, and can be employed to study crosstalk between calcium signaling, apoptosis, and membrane trafficking in a disease-relevant epithelial background.
This polyclonal knockout cell product is suitable for a wide range of experimental applications, including calcium signaling studies employing calcium flux assays, apoptosis research using Annexin V staining and Western blotting for Caspase-3 activation, and membrane trafficking analysis via immunofluorescence localization and co-immunoprecipitation with ALG2. Additional uses include drug screening for compounds that modulate ANXA11-associated pathways and cell migration assays to evaluate phenotypic changes. The combination of ANXA11 disruption and the HeLa cell platform enables robust, reproducible experimentation. For technical inquiries or additional information, please contact Ascent Research.
